Global R&D Pipeline
My Favorite
Hot Targets:
OX40
Back
Total number of drugs
87
Phase II and later clinical stages
11.5%
Involving companies
93
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENUM004 | ENUM004 | Monoclonal antibody | Neoplasms | OX40 agonists | Enumeral Biomedical Holdings, Inc. | - | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | - | ENUM004 | - | - | detail > | |
| WO2024193516 | WO2024193516 | Monoclonal antibody | Immune System Diseases Other Diseases | - | Bio-Thera Solutions, Ltd. | Bio-Thera Solutions, Ltd. | Discovery | - | - | - | - | - | - | - | - | - | WO2024193516 | - | - | detail > | |
| DF-004 | DF-004 | Monoclonal antibody | Digestive System Disorders | OX40 inhibitors | Shanghai Drug Farm Biological Technology Co., Ltd. | Shanghai Drug Farm Biological Technology Co., Ltd. | Discovery | Discovery | - | - | - | - | - | - | - | - | DF-004 | - | - | detail > | |
| BITT-OX40 | BITT-OX40 | Monoclonal antibody | Immune System Diseases Other Diseases | OX40 modulators | Boston Immune Technologies & Therapeutics, Inc. | Boston Immune Technologies & Therapeutics, Inc. | Discovery | - | - | - | - | - | - | - | - | - | BITT-OX40 | - | - | detail > | |
| WO2023061424 | WO2023061424 | Monoclonal antibody | Immune System Diseases Other Diseases | - | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.Maijin Biomedical Technology (Shanghai) Co., Ltd. | Maijin Biomedical Technology (Shanghai) Co., Ltd. | Discovery | - | - | - | - | - | - | - | - | - | WO2023061424 | - | - | detail > | |
| KN-052 | KN-052 | Bispecific antibody | Neoplasms Digestive System Disorders Skin and Musculoskeletal Diseases Urogenital Diseases | OX40 agonists PDL1 inhibitors Immunomodulators | Suzhou Alphamab Co., Ltd. | - | Discontinued (in Phase 1) | Discontinued (in Phase 1) | - | - | - | - | - | - | - | - | KN-052 | - | - | detail > | |
| Vonlerolizumab | Vonlerolizumab | Monoclonal antibody | Neoplasms Urogenital Diseases | OX40 agonists | Genentech, Inc. | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | Vonlerolizumab | - | - | detail > | |
| CN118987279 | CN118987279 | mRNA | Neoplasms Digestive System Disorders | - | 江苏教育学院 | - | Discontinued (in Discovery) | - | - | - | - | - | - | - | - | - | CN118987279 | - | - | detail > | |
| CN118085089 | CN118085089 | Nanobody | Neoplasms | - | The First Affiliated Hospital of Ningbo University | - | Discontinued (in Discovery) | - | - | - | - | - | - | - | - | - | CN118085089 | - | - | detail > | |
| WO2024141049 | WO2024141049 | Monoclonal antibody | Neoplasms | - | Gan & Lee Pharmaceuticals Co., Ltd. | Gan & Lee Pharmaceuticals Co., Ltd. | Discovery | - | - | - | - | - | - | - | - | - | WO2024141049 | - | - | detail > |
Total 87 data
1
2
3
4
5
6
7
8
9
